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Abstract: Fluorescence in situ hybridization (FISH) assay is considered the “gold standard” 
in evaluating HER2/neu (HER2) gene status. However, FISH detection is costly and time 
consuming.  Thus,  we  established  nuclei  microarray  with  extracted  intact  nuclei  from 
paraffin embedded breast cancer tissues for FISH detection. The nuclei microarray FISH 
(NMFISH) technology serves as a useful platform for analyzing HER2 gene/chromosome 
17  centromere  ratio.  We  examined  HER2  gene  status  in  152  cases  of  invasive  ductal 
carcinomas of the breast that were resected surgically with FISH and NMFISH. HER2 gene 
amplification status was classified according to the guidelines of the American Society of 
Clinical Oncology and College of American Pathologists (ASCO/CAP). Comparison of  
the cut-off values for HER2/chromosome 17 centromere copy number ratio obtained by 
NMFISH  and  FISH  showed  that  there  was  almost  perfect  agreement  between  the  two 
methods (κ coefficient 0.920). The results of the two methods were almost consistent for 
the evaluation of HER2 gene counts. The present study proved that NMFISH is comparable 
with FISH for evaluating HER2 gene status. The use of nuclei microarray technology is 
highly efficient, time and reagent conserving and inexpensive. 
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1. Introduction 
The HER2 gene and its protein product, a 185-kDa receptor tyrosine kinase, were initially identified 
in a rat glioblastoma model [1]. The 185 kDa protein encodes P185 or erbB2 and plays an important 
role in the regulation of cell growth [2]. HER2/neu gene is the most frequently amplified gene in breast 
cancer  (in  20~30%  of  cases)  [3].  Its  amplification  and  overexpression  are  associated  with  poor 
prognosis and resistance to cytotoxic drugs in breast cancer patients [4–6]. HER2 gene amplification 
has been used for predicting prognosis and guiding treatment of invasive ductal carcinoma of the 
breast with trastuzumab [7–9]. Accurate evaluation of HER2 status is important in the management of 
patients with candidacy for the HER2-targeting therapy. 
Internationally, the algorithm for HER2 testing is to perform either an immunohistochemistry (IHC) 
method to assess HER2 overexpression, in which patients with equivocal HER2 expression (2+) are 
further tested to assess gene amplification of HER2 using the fluorescence in situ hybridization (FISH) 
method, or directly assess the HER2 status by the FISH method [10–12]. 
Researchers also use chromogenic in situ hybridization (CISH) or dual-color CISH for simultaneous 
detection of the HER2 gene and the centromere region of chromosome 17 [13,14]. The FISH assay is 
technically reproducible and is a preferred method for evaluating HER2 gene status [15]. 
Tissue microarrays, also called tissue chips [16], are an ordered array of tens of thousands of tissue 
cores in a single paraffin block. This allows for thousands of genes to be monitored simultaneously for 
expression  level  and  comparisons  to  be  made  between  many  different  tissues  on  one  glass  slide. 
Christopher et al. [17] introduced methods to make cultured cells into microarrays. It has the same 
advantage  as  tissue  microarray.  We  established  the  nuclei  microarray  using  nuclei  for  the  FISH, 
mRNA in situ hybridization and cytochemistry study [18]. 
Nuclei microarray technology was used in the FISH detection of  the HER2 gene. This method 
allows  for  the  simultaneous  detection  of  multiple  specimens  with  high  comparability  and  cost 
efficiency. This study has investigated the concordance and correlation between fluorescence in situ 
hybridization (FISH) using conventional tissue  sections and nuclei microarray fluorescence in situ 
hybridization in breast cancer patients. 
2. Results and Discussion 
2.1. Results 
HER2 status for all samples was determined by conventional FISH and nuclei microarray FISH. 
Signals  for  both  HER2  and  chromosome  17  centromere  were  clearly  detected  using  the  nuclei 
microarray method (Figure 1). Separate signals could be counted without difficulty for non-amplified, 
equivocal, and amplified HER2 samples. Of the 152 cases analyzed, 42 were found to be amplified Int. J. Mol. Sci. 2012, 13  5521 
 
 
both by conventional FISH and Nuclei Microarray FISH (NMFISH) (ratio of HER2/CEP17 more than 
2.2), giving an amplification rate of 27.6%. 
Figure 1. HER2 gene status detected by NMFISH (HER2 signals red, CEP17 green) 100× 
objective. (a) HER2 gene non-amplified; (b) HER2 gene amplified. 
 
Nuclei Microarray FISH versus Conventional FISH 
Of the 152 cases, the NMFISH method detected HER2 amplification (HER2 ratio above 2.2) in  
44 cases, equivocal (ratios from 1.8 to 2.2) in 22 cases and 86 cases showed non-amplified (ratios less 
than  1.8),  the  conventional  FISH  method  detected  HER2  amplification  in  42  cases,  equivocal  in  
23  cases  and  87  cases  showed  non-amplified  HER2.  The  agreement  between  NMFISH  and 
conventional FISH was almost perfect: 95.4% (145/152), κ coefficient = 0.920 (Table 1). 
Table  1.  Comparison  of  HER2  gene  amplification  status  by  fluorescence  in  situ 
hybridization (FISH) vs. nuclei microarray in situ hybridization. 
  Nuclei Microarray FISH 
FISH  Non-Amplified *  Equivocal 
§  Amplified 
‡  Total 
Non-amplified *  84  3  0  87 
Equivocal 
§  2  19  2  23 
Amplified 
‡  0  0  42  42 
Total  86  22  44  152 
Overall agreement: 0.954, κ coefficient = 0.920; * HER2/CEP17 ratio < 1.8; 
§ HER2/CEP17 ratio ≥ 1.8, < 2.2;  
‡ HER2/CEP17 ratio ≥ 2.2. 
There was no significant difference between the two methods using the McNemar–Bowker Test  
(P = 0.333). 
There were two discrepant cases that showed non-amplification by nuclei microarray FISH but 
equivocal amplification by conventional FISH. Three cases showed equivocal by nuclei microarray 
FISH but non-amplified by conventional FISH and two showed amplified by nuclei microarray FISH 
but equivocal amplification by conventional FISH. The HER2/CEP17 ratios of these seven cases are Int. J. Mol. Sci. 2012, 13  5522 
 
 
detailed in Table 2. HER2/CEP17 ratios detected with the two diagnostic methods were very similar 
and close to the cut-off value. This may have caused the differences in diagnoses. 
Table 2. Discrepant results of mean copy number ratios of HER2 gene and chromosome 17 
centromere  by  fluorescence  in  situ  hybridization  (FISH)  and  nuclei  microarray  in  situ 
hybridization (NMFISH) in seven breast cancer samples. 
Case #  NMFISH/FISH Status  NMFISH  FISH 
1#  Non-amplified/equivocal  1.74  1.86 
2#  Non-amplified/equivocal  1.67  1.85 
3#  Equivocal/Non-amplified  1.87  1.71 
4#  Equivocal/Non-amplified  1.91  1.65 
5#  Equivocal/Non-amplified  1.86  1.74 
6#  Amplified/equivocal  2.39  2.15 
7#  Amplified/equivocal  2.45  2.13 
2.2. Discussion 
Trastuzumab therapy has been used for the treatment of metastatic breast cancer for some years. Due 
to the development of adjuvant trastuzumab therapy, pathological laboratories are currently requested to 
perform  HER2  status  assays  for  all  newly  diagnosed  breast  cancers.  The  ASCO/CAP  guidelines 
recommend the HER2 status to be optionally determined by IHC or FISH. In most laboratories, IHC is 
done first. In cases where the primary immunohistochemical result is equivocal at the protein level, such 
as an IHC score of 2+, faint staining or other artifacts, an additional test is strongly recommended to 
clarify the HER2 status at the genomic level to determine amplification or nonamplification. Thus, the 
need for reliable diagnostic and cost-effective HER2 gene tests is rapidly increasing. 
Tissue microarrays, also called tissue chips, are a novel technology invented by Konenen et al. [19], 
based on cDNA microarrays in 1998.  It is a high throughput and resource conserving technology 
where tens of thousands of typical minute cylindrical tissue samples or cells from hundreds of different 
tumors are transferred to a new paraffin block. Tissue microarrays can be used in the detection of DNA, 
RNA or protein in various clinical or basic research areas [20,21]. 
Christopher et al. [17] introduced methods to make cultured cells into microarrays. This inspired us 
to make nuclei microarray with nuclei extracted from the paraffin embedded tissues for the FISH 
detection.  The  present  study  proved  this  method  was  feasible  for  the  detection  of  HER2  gene 
amplification in breast cancer. 
During the process of making the nuclei microarray, 30-μm thick paraffin sections were cut for the 
extraction of nuclei instead of using the 4-μm thick sections used during the conventional FISH detection. 
This  ensured  that  the  nuclei  were  intact  without  being  sectioned  and  the  genetic  DNA  material  
was retained. 
In the majority of the cases, the FISH method was performed successfully on nuclei microarray and 
almost perfect agreement with the FDA-approved HER2 FISH pharmDx method was revealed. Similar 
reagents  and handling in the pretreatment,  denaturation, hybridization and stringent  washing steps 
were used in the two methods. One hundred samples can be detected simultaneously using this method 
with the same amount of reagents previously needed for one entire specimen, greatly reducing the cost. Int. J. Mol. Sci. 2012, 13  5523 
 
 
The nuclei microarray FISH technology is advantageous for its high efficiency and low background 
compared to the conventional FISH using paraffin embedded tissue sections. The entire tissue section 
was used for the extraction of nuclei from multiple areas of the tumor. Each microarray disk contains 
more than five hundred cells [18], which are sufficient for the FISH detection. 
During the conventional FISH detection using paraffin embedded tissue sections, variations can 
occur due to loss of the genetic DNA material occurring when the tissue blocks were sectioned. In the 
present study, we did not find this discrepancy since the ratios between HER2 signal and CEP17 were 
used to evaluate the HER2 gene amplification in breast cancer. The probability of the signal losses for 
HER2 and CEP17 due to sectioning is the same in this experiment. Thus, the nuclei microarray FISH 
and conventional FISH are both applicable for detecting HER2 gene amplification in breast cancer. 
The present study compared nuclei microarray FISH and conventional FISH in detecting HER2 
gene amplification in breast cancer. The McNemar–Bowker test revealed that there was no significant 
difference between the two methods (P = 0.333). κ test revealed there was almost perfect agreement 
between the two methods (κ coefficient = 0.920). There are seven cases with discrepant results while 
the ratios are close to the diagnostic cut-off value. This may be caused by the heterogeneity of the 
tissue specimens. 
3. Experimental Section 
A retrospective study was conducted over one and a half years to reveal 152 cases of invasive 
ductal carcinomas of the breast (aged 31 to 83 years, median 49 years) that had been evaluated for the 
HER2 gene by conventional FISH on formalin-fixed paraffin embedded tissue sections and nuclei 
microarray FISH using nuclei of breast cancer cells. 
All patients underwent a radical operation and the diagnosis was confirmed in the Department of 
Pathology,  General  Hospital  of  Shenyang  Military  Area  Command.  The  clinical  stage  was  stage  
I–IIIC. Tissue blocks were available from all patients. Samples from patients with a previous history of 
breast cancer, having received neoadjuvant therapy, late staged metastatic cancer or multiple primary 
cancers were excluded from this study. 
A  stained  section  of  each  tumor  sample  was  prepared  from  blocks  to  confirm  the  diagnosis. 
Representative tumor areas for nuclei extraction were selected to construct the nuclei microarray. An 
adjacent 4-μm thick section was also obtained for conventional FISH analysis. 
3.1. Nuclei Microarray Construction 
Methods for constructing nuclei microarrays (NMAs) and extraction of nuclei from paraffin-embedded 
tissue blocks have been described elsewhere [18,22]. Briefly, a blank cell microarray paraffin block 
was made in a 10 ×  10 matrix using a manual arrayer (Beecher Instruments, Sun Prairie, WI, USA, 
MTA-1). Thirty-micrometer-thick sections were cut from the paraffin block and placed on a glass slide 
as a mold for holding nuclei suspensions. For each specimen, four pieces of 30-μm thick paraffin 
sections were cut and the tissue sections were placed into a 1.5 mL microcentrifuge tube. Nuclei were 
extracted after deparaffination and enzyme digestion [18]. During the process of nuclei extraction, 
tissue  debris  was  separated  from  the  nuclei  and  removed.  This  ensured  a  clear  background  in 
fluorescence in situ hybridization (FISH) testing. Cell density was adjusted to 1 ×  10
4 cells/µL with Int. J. Mol. Sci. 2012, 13  5524 
 
 
phosphate buffered saline (PBS, pH 7.4). Pretreated nuclei were injected into each well of the paraffin 
mold using a  sample injector.  This  step is  crucial to achieve the precise injection of 0.3 µL  cell 
suspension into each well. The slides with cells were heated at 65 °C  for one hour and then dewaxed in 
xylene twice for 40 and 20 minutes, respectively. The cell microarray was ready after open-air drying. 
3.2. Nuclei Microarrays Fluorescence in Situ Hybridization (NMFISH) 
NMFISH  analysis  was  evaluated  using  the  PathVysion  HER2  DNA  Probe  Kit  (Abbott-Vysis, 
Downers Grove, IL, USA). The hybridization mixture included a centromere 17 specific Spectrum 
Green-labeled DNA probe and HER2/neu specific Spectrum Orange-labeled DNA probe. 
The NMA slides were dried in a 65 ° C oven for one hour, fixed with methanol-glacial acetic acid 
(3:1) for one hour. After air drying, slides were placed in citrate buffer (pH 6.0) and incubated for  
10 minutes in a microwave oven, then transferred to freshly prepared 0.4% pepsin solution (0.16 g 
pepsin, 2850 U/mg solid, in 40 mL of 0.9% sodium chloride, pH 1.5) and dehydrated through a series 
of  graded  ethanol.  Ten  microliters  of  probe  solution,  as  recommended  by  the  manufacturer,  was 
applied to the slide, protected with a coverslip, and sealed with a continuous bead of rubber cement. 
Slides were processed with a HYBrite instrument (Vysis, Downers Grove, IL, USA) programmed with 
a melt temperature of 82 ° C for 10 minutes and hybridization temperature of 37 ° C for 16 hours. After 
hybridization, the coverslip was removed and the slides were washed in stringent wash buffer first 
briefly at room temperature then in a 65 ° C hot solution for 10 minutes. The slides were counterstained 
with diamidinophenyl-indole. The samples were analyzed under a 100×  oil immersion objective using 
an Olympus BX-61 fluorescence microscope with appropriate filters. 
3.3. Conventional Fluorescence in Situ Hybridization (FISH) 
FISH was performed on 4-μm sections using the same probe as NM FISH. Tissue pretreatment was 
performed  using  the  paraffin  pretreatment  kit  I  (Gene  Tech  Company  02J02-032)  as  per  the 
manufacturers’ instructions. For each case, thirty invasive tumor cells were counted by two different 
scorers (XB and HJ). 
3.4. Evaluation of HER2 Gene Amplification 
HER2 gene amplification status was classified according to the following criteria (ASCO/CAP) [11]. 
FISH signals were assessed by two independent assessors examining 30 non-overlapping nuclei for 
each tissue. The number of red signals (HER2) and green signals (CEP17) for each cell was recorded. 
Calculation of the HER2/CEP17 ratio was performed. 
The results were graded as HER2/CEP17 ratio: Negative HER2 gene amplification was defined as a 
HER2/CEP17  ratio  of  less  than  1.8.  Equivocal  HER2  gene  amplification  was  defined  as  a 
HER2/CEP17 ratio between 1.8 and 2.2. Positive HER2 gene amplification was defined as a HER2 
CEP17 ratio of more than 2.2. Int. J. Mol. Sci. 2012, 13  5525 
 
 
3.5. Statistics 
Comparisons  between  FISH  using  conventional  paraffin  embedded  tissue  sections  and  nuclei 
microarray FISH were analyzed using McNemar–Bowker Test. Concordance data obtained from both 
the conventional FISH and nuclei microarray FISH were determined. The κ statistic method was used 
to measure the agreement of HER2/CEP17 ratio between the two assays. The κ statistic evaluates the 
level  of  agreement  after  adjustment  for  agreement  expected  to  occur  by  chance  alone  with  a  κ 
coefficient  >0.80  indicating  near-perfect  agreement,  values  of  0.61  to  0.80  substantial  agreement, 
values  of  0.41  to  0.60  moderate  agreement,  values  of  0.21  to  0.40  fair  agreement,  
values >0 to 0.20 slight agreement, and values of 0 no agreement or a random association [23]. SPSS 
(version 13.0; SPSS Inc.: Chicago, IL, USA, 2004) was used for all statistical analysis. A P value less 
than 0.05 was regarded as statistically significant. 
4. Conclusions 
Nuclei  microarrays  can  be  used  in  Fluorescence  in  situ  Hybridization  in  assessing  HER2  gene 
amplification in breast cancer. The use of nuclei microarrays methodology is highly efficient, time and 
reagent conserving and low cost. The disadvantage is that it takes time to construct the nuclei microarray. 
However, the time needed for constructing the nuclei microarray is a small fraction of the overall time 
compared to the time needed to carry out an experiment from sectioning the 152 paraffin embedded 
blocks,  performing  the  FISH  experiment  on  the  slides,  and  imaging,  processing  and  analyzing  the 
samples. Nuclei microarray FISH technology produces reproducible and identical results when compared 
to conventional FISH. It is applicable for use in research. In clinical settings, if there were a large number 
of specimens needed to be detected by FISH, nuclear array FISH could be considered. 
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